SCHEMBL6038772

SCHEMBL6038772

Cc1ccccc1S(=O)(=O)Nc1nc2ccccc2nc1OCCN(C)c1ccccc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.53
RXFP1 Q9HBX9 4/20 0.53
L3MBTL1 Q9Y468 1/20 0.53
KDM4E B2RXH2 7/20 0.50
HPGD P15428 4/20 0.50
LMNA P02545 1/20 0.50
HSD17B10 Q99714 1/20 0.50
KMT2A Q03164 6/20 0.47
MEN1 O00255 5/20 0.47
PKM P14618 1/20 0.46
TSHR P16473 1/20 0.44
PPARG P37231 1/20 0.44
NCOA2 Q15596 1/20 0.44
NCOA1 Q15788 1/20 0.44
MAPT P10636 2/20 0.43
PLA2G1B P04054 1/20 0.43
HTT P42858 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43
ATG4B Q9Y4P1 1/20 0.43
GAA P10253 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6038980 0.87 KDM4E (0.67) ALDH1A1RXFP1KDM4EHPGDLMNA
SCHEMBL6039067 0.86 ALDH1A1 (0.51) ALDH1A1RXFP1L3MBTL1KDM4EHPGD
SCHEMBL6038440 0.85 KDM4E (0.58) ALDH1A1RXFP1KDM4EHPGDLMNA
SCHEMBL6038832 0.84 RXFP1 (0.58) ALDH1A1RXFP1L3MBTL1KDM4EHPGD
SCHEMBL6038436 0.83 KDM4E (0.55) ALDH1A1KDM4EHPGDLMNAHSD17B10
SCHEMBL6038536 0.83 ALDH1A1 (0.57) ALDH1A1RXFP1L3MBTL1KDM4EHPGD
SCHEMBL6038323 0.82 KDM4E (0.57) ALDH1A1RXFP1L3MBTL1KDM4ELMNA
SCHEMBL6038905 0.82 KMT2A (0.68) ALDH1A1RXFP1L3MBTL1KDM4ELMNA
SCHEMBL6039072 0.82 KMT2A (0.70) ALDH1A1RXFP1KDM4ELMNAHSD17B10
SCHEMBL6038702 0.82 ALDH1A1 (0.56) ALDH1A1RXFP1L3MBTL1KDM4EHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060004029-A1 Nitrogen-containing aromatic derivatives EISAI R&D MANAGEMENT CO., LTD. (JP) 2006-01-05 US disclosed
US-20060004010-A1 Ccr4 antagonist and medical use thereof ONO PHARMACEUTICAL CO., LTD. (JP) 2006-01-05 US disclosed
EP-1541563-A1 CCR4 ANTAGONIST AND MEDICINAL USE THEREOF ONO PHARMACEUTICAL CO., LTD. (JP) 2005-06-15 EP disclosed
EP-1522540-A1 AZAARENE DERIVATIVES Eisai Co., Ltd. (JP) 2005-04-13 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004010-A1 Ccr4 antagonist and medical use thereof CCR4, CCR1, CCR9 ALDH1A1 2902/4885RXFP1 142/4885L3MBTL1 2666/4885
US-20060004029-A1 Nitrogen-containing aromatic derivatives NR0B2, NR0B1, NR4A1 ALDH1A1 1501/4885RXFP1 144/4885L3MBTL1 2633/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.